Navigation Links
4th ESU master class on medical treatment for urological cancer held in Barcelona, Spain
Date:6/18/2009

Arnhem, June 2009 The 4th ESU Master class on medical treatment for urological cancer is organised by the European School of Urology (ESU) on 27-28 June 2009 at the Barcel Hotel Sants in Barcelona, Spain. The format consists of three modules. Module 1 is entitled 'Hormonal and intravesical treatment and chemoprevention', module 2 'Immunotherapy and targeted therapies' and module 3 'Systemic cytotoxic chemotherapy and palliation'.

Each module comprises short state-of-the-art lectures followed by debates, case reports and interactive discussions. supplemented with case discussions and presentations. For the first time an online pre-assessment is included in the programme.

Professor Hein van Poppel, ESU course director: "The pre-assessment is meant to determine the level of a participant's knowledge before the start of the Masterclass. It is held online and consists of 20 multiple choice questions. The faculty will review the results and adjust the content of their lectures accordingly".

A post-assessment takes place after the last lecture and consists of 100 multiple choice questions to test the participant's knowledge on the topics taught during the ESU Masterclass.

This teaching programme has been developed by close collaboration between the European Association of Urology (EAU), the European School of Urology (ESU) and the European Board of Urology (EBU). "With rapid advances in cancer research, the oncologically oriented urologist requires insights on the clinical applicability and impact of the latest range of surgical and medical treatment strategies. The Masterclass is a prime venue to scrutinise current practices and survey the latest therapies that are still being tried or tested in various medical disciplines involved in cancer therapy", says Professor Ziya Kirkali, ESU course director. The ESU aims to provide a comprehensive update for urologists, but the Masterclass is open to other specialists, such as medical
'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
2. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
3. Charles A. Peck, M.D., F.A.C.P. Joins LifeMasters as New Medical Director Focused on Client Experience
4. Mastering Challenges & Measuring Successes for Quality Initiatives in Sales, Marketing and Product Development
5. Nursing Scholarships Offered by Western Governors University for Masters Degree Programs
6. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
7. LifeMasters Receives Full URAC Disease Management Accreditation
8. McMaster test detects the most prevalent respiratory viruses
9. The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida
10. Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits
11. LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... BROOK, Ill., Dec. 7 The University ... (AMC) members for their achievements in UHC,s Supply ... organizations are noted for modeling best practices in ... http://www.newscom.com/cgi-bin/prnh/20091207/CG21708 ) ,, The winners were determined ... that includes contract portfolio participation and use of ...
(Date:12/6/2009)... factor, researchers say , , SUNDAY, Dec. 6 (HealthDay ... the main tumor to other parts of the body ... which may prove a promising target for new drugs ... Previous studies have shown that TGFb (transforming growth factor ... new study, a team from Cancer Research UK used ...
(Date:12/6/2009)... 6 Blood clotting, or coagulation, is ... a blood vessel is injured. Sometimes, however, clots ... obvious injury or do not dissolve naturally, a ... at the 51st Annual Meeting of the American ... using the anticoagulants aspirin and heparin with the ...
(Date:12/5/2009)... has shown in a phase 1/2 clinical trial ... treatment of patients newly diagnosed with multiple myeloma, a ... researchers from Dana-Farber Cancer Institute. , Partial responses or ... treated with the drug combination in the multi-center study, ... rate" in the phase 2 population, reports Paul G. ...
(Date:12/5/2009)... Leukemia and myeloproliferative disorders are serious and often ... 51st Annual Meeting of the American Society of ... diagnostic methods for patients suffering from acute promyelocytic ... and myelofibrosis that are based on a better ...
Breaking Medicine News(10 mins):Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... journal publisher, is proud to be participating in a ... today by the Council of Science Editors. , The ... stimulate interest and debate on the crucial matters of ... both developed and developing countries will simultaneously publish papers ...
... says, , , MONDAY, Oct. 22 (HealthDay News) -- If you,re ... says a common device can determine whether someone is a ... used to ferret out people who hide a cigarette ... show patients what smoking is doing to their bodies, he ...
... Late-breaking results from the ENDEAVOR IV trial, presented at ... Research Foundation, show that the Endeavor zotarolimus-eluting stent met ... profile (equivalent rates of death, heart attack, and repeat ... , In addition, the Endeavor stent showed a ...
... Bayer Consumer Care announces,the availability of the ... Sinus), combining a long-lasting nasal decongestant with the,pain-relieving ... from,multiple sinus and pain symptoms. The combination ... in a recent survey of adults who suffer ...
... of,the nation,s leading information systems publications, has ranked ... top 500 innovators of information,technology. Highmark, which ... and,fourth in the insurance industry overall, moved up ... Tabor, Highmark,s senior vice president of information services ...
... than four percent lower, BLOOMINGTON, Minn., Oct. ... provide new evidence that members,who have health savings ... and are more engaged in seeking out more ... adjusted for illness burden, health,care costs were 4.4 ...
Other Medicine News:Health News:9 SAGE journals participate in global theme issue on poverty and human development 2Health News:Blood Test Catches Secret Smokers 2Health News:Blood Test Catches Secret Smokers 3Health News:ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent 2Health News:ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication 2Health News:ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication 3Health News:National Magazine Ranks Highmark 62nd Among Nation's 500 Most Innovative Users of Information Technology 2Health News:New Study Shows Lower Costs, Increased Consumer Engagement in Account-Based Health Plans 2
(Date:12/4/2009)... inexpensive computer tool that measures volume changes in the ... by a CT scanner can rule out non-cancerous ones ... true cancers with fewer, less expensive and less invasive ... diagnostic guidelines are described in a paper published yesterday ...
(Date:12/4/2009)... Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) announced that on ... Reorganization and related amended Disclosure Statement with the United States ... A hearing to consider the adequacy of the Disclosure Statement ... on the confirmation of the Plan scheduled for January 7, ...
(Date:12/4/2009)... 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... and webcast. Principal investigators will discuss the data ... as featured at the 51st American Society of Hematology ... 9:00 a.m. CT/10:00 a.m. ET on Monday, December 7, ...
Breaking Medicine Technology:European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex 28R 29 12913 1China Clean Energy Provides Business Update 12912 1China Clean Energy Provides Business Update 12912 2China Clean Energy Provides Business Update 12912 3US Farms Inc Showcasing Aloe Vera Product Line at Natural MarketPlace 2009 50872 1US Farms Inc Showcasing Aloe Vera Product Line at Natural MarketPlace 2009 50872 2
... able to stimulate insulin,release, TARRYTOWN, N.Y., March ... today results of two clinical,studies conducted in ... Gastroenterology and Hepatology,University Hospital Basel in Basel, ... peptide-1 (7-36 amide) (GLP-1) was to,establish the ...
... Survey Shows 89% of Patients Prefer Orapred ... 2007 /PRNewswire/ -- Alliant,Pharmaceuticals announced today survey ... sodium phosphate,orally disintegrating tablets) over liquid steroids.(1) ... survey involving more than,900 children (n=973), showed ...
Other Medicine Technology:Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 2Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 4Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 5Orapred ODT Tastes Good 2Orapred ODT Tastes Good 3
... an integral part of the enzymatic cascade ... as well as the degradation of Bradykinin. ... is primarily located in endothelial cells. ACE ... for sarcoidosis and myocardial infarction but is ...
... and quantitative evaluation of pancreatic b-cell function is ... post-diagnostic study of the natural history of diabetes ... as a guide to the correct choice of ... to assess b-cell function because of the ...
... hormone responsible for the control of glucose metabolism. ... the islets of Langerhans as the precursor, proinsulin, ... Both are secreted in equimolar amounts into ... is comprised of two polypeptide chains, the A-chain ...
... quantitative evaluation of pancreatic -cell function is not ... study of the natural history of diabetes mellitus, ... a guide to the correct choice of treatment. ... -cell function because of the large and variable ...
Medicine Products: